4915W-10 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Te

A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

Type of Study
Neuroscience - Brain Tumor
Short Description

To compare the efficacy and safety outcome of newly diagnosed GBM patients treated with NovoTTF-100A concomitant to Temozolomide to those treated with Teozolomide alone.

Status
Open
Principal Investigator
John Henson, MD
Eligibility Notes

Inclusion:

  • Diagnosis of GMB
  • 18 years of age and older
  • Received maximal debulking surgery and radiotherapy with Temozolomide.
  • Life expectancy at least 3 months

Exclusion:

  • Implanted pacemaker, defibrillator or deep brain stimulator

Contact Name
Jeannie Steed
Phone
206-386-3878
Email
jeannie.steed@swedish.org